Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Medicine and Dentistry

• All Cause Mortality 16%
• Anticoagulant Therapy 33%
• Antiplatelet 16%
• Antithrombotic 100%
• Apoplexy 50%
• Atrial Fibrillation 100%
• Clinical Trial 16%
• Coronary Artery Disease 33%
• Diabetes 33%
• Fibrillation 100%
• Major Bleeding 16%
• Prevalence 16%
• Vitamin K Antagonist 33%

Biochemistry, Genetics and Molecular Biology

• All Cause Mortality 33%
• Anticoagulation 33%
• Atrial Fibrillation 100%
• Clinical Trial 33%
• Prevalence 33%
• Vitamin K 66%

Keyphrases

• High Stroke Risk 14%